FEATURED, Neoadjuvant Treatment, News, BRCA, PARP Inhibitors
Neoadjuvant Single-Agent PARP Inhibitor Appears Promising in BRCA Patients
BRCA patients may be able to take only one pill a day in a neoadjuvant setting The results of a small phase II trial suggest that the PARP inhibitor, talazopari...
Subscribe to Updates
TOPICS
- FEATURED (131)
- News (76)
- Research (63)
- Industry (44)
- Opinion (35)
- Risk Assessment (33)
- Genetics (23)
- Genomics (16)
- Cases (14)
- Surgery (13)
- Video (12)
- Resources (11)
- Coding (10)
- Genetic Testing (9)
- Tools (9)
- COVID (7)
- Imaging (7)
- Neoadjuvant Treatment (7)
- Margins (6)
- Radiation (6)
- Biopsy (5)
- Breast Cancer (5)
- Biology (4)
- Chemotherapy (3)
- Oncoplastic (3)
- Tumor Localization (3)
- BRCA (2)
- Events (2)
- Germline (2)
- Lymphedema (2)
- Metastatic breast cancer (2)
- Regional Management (2)
- Techniques (2)
- Uncategorized (2)
- Biologic Therapy (1)
- CRISPR (1)
- Diagnosis (1)
- Fertility (1)
- Genetic Engineering (1)
- Health care economics (1)
- Histology (1)
- Neoadjuvant Therapy (1)
- PARP Inhibitors (1)
- Pregnancy (1)
- Risk (1)
- Subtypes (1)
- links (1)